PURPOSE: A composition for treating Epstein-Barr virus-positive gastric cancer is provided to suppress proliferation of Epstein-Barr virus and to effectively treat Epstein-Barr virus-positive gastric cancer when ganciclovir and gemcitabine are combined. CONSTITUTION: A pharmaceutical composition for treating Epstein-Barr virus-positive gastric cancer contains an anti-herpes viral agent and 1 ng/ml or greater of gemcitabine. The anti-herpes viral agent is selected among ganciclovir acyclovir penc...

FIELD: medicine pharmaceutics.SUBSTANCE: claimed are: application of silibinin component of general formula(I) for obtaining medication for parenteral introduction for trweatment of viral hepatitis with medication optionally containing cyclodextrin and/or phospholipid and set of similar purpose which includes said silibinin component and other medication representing one or several pharmaceutical agents from: arginine glutamate silymarin citiolone epodemiol ornithine oxoglurate tidiacic arginine...

1. A suspension consisting of a sterile solution containing 1 to 1.5% mass/volume of a viscosity modifier 0.5 to 1.5% of a surfactant and 3.5 to 4.5% of an isotonicity agent and of biodegradable microspheres which release an anticancer agent which are coated with a polymer the proportion of the microspheres representing 200 to 300 mg/ml of sterile solution. 2. The suspension as claimed in claim 1 characterized in that the microspheres consist of 15 to 35% by weight of anticancer agent and of 65%...

Biodegradable microspheres are prepared by dispersing an anticancer agent in an organic solvent with vigorous stirring addi polymer mixing with an aqueous phase to form an emulsion.The organic solvent is extracted by addition of water and the suspens of microspheres is filtered off.Biodegradable microspheres are prepared by dispersing an anticancer agent in an organic solvent with vigorous stirring add a polymer mixing with an aqueous phase to form an emulsion.The organic solvent is extracted by...

Biodegradable microspheres are prepared by dispersing an anticancer agent in an organic solvent with vigorous stirring addi polymer mixing with an aqueous phase to form an emulsion. The organic solvent is extracted by addition of water and the suspens of microspheres is filtered off. Biodegradable microspheres are prepared by dispersing an anticancer agent in an organic solvent with vigorous stirring add a polymer mixing with an aqueous phase to form an emulsion. The organic solvent is extracted...

PURPOSE: To obtain the subject safe and costwisely advantageous composition by combining a carrier with an antiviral nucleotide analog or its salt and a specific ribonucleotide-reductase-inhibiting peptide derivative or its salt.CONSTITUTION: This pharmaceutical composition for treating herpes of mammal is obtained by formulating a carrier which is permissible as a medicine or a veterinary medicine with an effective amount of antiviral nucleotide analog (especially preferably vidarabine idoxurid...

A pharmaceutical composition and method for the treatment of herpes simplex infections is disclosed. The composition contains a quaternary ammonium compound such as cetrimide or benzalkonium chloride and an antiviral agent such as acyclovir, bromoinyldesoxuridine, 3-fluorothymidine, idoxuridine, propyl gallate, proanthocyanides or glucosamine. The compound can also contain a plant extract such as camomile.

A novel formulation (I) contains (A) caffeine (B) one or more synthetic inhibitors of herpes simplex virus (HSV) replication and (C) a formulation base. (A) is contained at 0.3-100mg and (B) at 0.001-50mg both per g or ml of (C). (B) is e.g. acyclovir brivudine foscarnet idoxuridine or 9-(2-phosphonylmethoxyethyl)-adenine. (C) is an ointment cream lotion or solution.

A pharmaceutical composition and method for the treatment of herpes simplex infections is disclosed.The composition contains a quaternary ammonium compound such as cetrimide or benzalkonium chloride and an antiviral agent such as acyclovir bromoinyldesoxuridine 3-fluorothymidine idoxuridine propyl gallate proanthocyanides or glucosamine.The compound can also contain a plant extract such as camomile.(From US6284289 B1)

A novel formulation (I) contains (A) caffeine, (B) one or more synthetic inhibitors of herpes simplex virus (HSV) replication and (C) a formulation base. (A) is contained at 0.3-100mg and (B) at 0.001-50mg, both per g or ml of (C). (B) is e.g. acyclovir, brivudine, foscarnet, idoxuridine or 9-(2-phosphonylmethoxyethyl)-adenine. (C) is an ointment, cream, lotion or solution.